3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)-phenylamino]-methyl}-1-methyl1H-benzimidazol-5-carbonyl)-pyridine-2 -yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament

Details for Australian Patent Application No. 2010201457 (hide)

Owner Boehringer Ingelheim International GmbH

Inventors Sobotta, Rainer; Sieger, Peter; Schmid, Rolf

Agent Davies Collison Cave

Pub. Number AU-B-2010201457

Parent 2004274139

Filing date 13 April 2010

Wipo publication date 6 May 2010

Acceptance publication date 10 May 2012

International Classifications

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

A61K 31/4439 (2006.01)

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

29 April 2010 Complete Application Filed

6 May 2010 Application Open to Public Inspection

  Published as AU-B-2010201457

10 May 2012 Application Accepted

  Published as AU-B-2010201457

6 September 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010201458-Use of mGluR5 (esp. AFQ056) in GI (esp. GERD)

2010201456-Fiber optic cables and assemblies for fiber toward the subscriber applications